InvestorsHub Logo
Followers 280
Posts 33245
Boards Moderated 1
Alias Born 11/14/2013

Re: longusa post# 18128

Monday, 09/01/2014 10:24:57 AM

Monday, September 01, 2014 10:24:57 AM

Post# of 720872
Regardless as to whether regulatory agencies take some data into significant account (or not), I am certain NWBO is additionally looking at Gorter and Israel data. I'm relatively confident the former avoids chemo and probably radiation in most cases, and I suspect the latter is not beholden to radiation therapy. Thus, there is probably quite a bit of alternative CD4 (non radiation) data that NWBO observes on a daily basis allowing them to compare it to CD4 (radiation) data from the prior L trials, current advanced L phase 2 trial, the informational arm, and other small clinical study L data. I am still curious to see what the current blinded larger phase 3 study will reveal regarding white blood cell recovery after dendritic cell therapy with DCVax-L. I suspect the WBC count may in fact recover in some cases. My assumption is based upon the average 80% RR NWBO is witnessing across the board (not including unpublished/blinded phase 3 data).

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News